The PROFTH project aims at developing the robotics and AI technologies to enable focal therapies for prostate cancer (PCa) using the robotic positioned developed during the ERC-PoC PROST. PCa therapy is lagging about 10 years from...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
EUIN2015-62414
ROBOTICA AVANZADA PARA LA CIRUJIA MINIMAMENTE INVASIVA ASIST...
12K€
Cerrado
DPI2008-06775-C02-01
ESTRATEGIAS DE CONTROL INTRAOPERATORIO DE UN ROBOT QUIRURGIC...
12K€
Cerrado
SSB2
Surgify Safety Burrs for safer bone surgery
3M€
Cerrado
PID2021-125050OA-I00
ROBOT QUIRURGICO PARA EL ASPIRADO AUTONOMO DE SANGRADO DURAN...
90K€
Cerrado
Información proyecto PROFTH
Duración del proyecto: 19 meses
Fecha Inicio: 2023-10-31
Fecha Fin: 2025-06-30
Líder del proyecto
NEEDLEYE ROBOTICS SRL
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
150K€
Descripción del proyecto
The PROFTH project aims at developing the robotics and AI technologies to enable focal therapies for prostate cancer (PCa) using the robotic positioned developed during the ERC-PoC PROST. PCa therapy is lagging about 10 years from e.g. kidney and breast therapies, that has shifted from invasive surgery to percutaneous ablation of the tumour. Several trials are acquiring the clinical evidence to support the shift from radical prostatectomy to PCa focal therapy, considering the multifocal aspect of PCa and the need to preserve the surrounding anatomical structures. Key to focal therapies is the ability to accurately and repeatably positioning the ablation device in the PCa area and to achieve the minimal tissue removal that satisfies the safety margins around the tumor and leaves the other structures untouched. The problem of accurately positioning a biopsy needle in the PCa area has been solved by the PROST project, thus we want to build on this capability to set the basis of PCa focal therapy. To achieve this goal, PROFTH will address three main objectives: 1. definition of the joint requirements between clinical needs, capabilities of the current ablation devices and positioning accuracy of PROST; 2. development of the digital twin of the pelvic area to integrate the medical information of the patient; and 3. develop a planning algorithm that will compute the position of the ablation devices in the patient PCa. We will test the developed algorithms with laboratory and ex-vivo experiments using the ablation systems available at the University Hospital of Verona.